Five experts in the field of MDS highlight recent data updates, including those presented at the 2022 American Society of Hematology (ASH) Annual Meeting.
EP. 1: MDS: Typical Patient Presentation, Diagnostic Process, and Evolving TerminologyJanuary 18th 2023
Moderator Rami Komrokji, MD, introduces the panel and invites expert pathologist Sanam Loghavi, MD to lead a discussion on the typical patient presentation and diagnostic process in MDS, which was recently renamed as ‘myelodysplastic neoplasms’ in the 2022 5th edition of the World Health Organization (WHO) classification of the disease state.
EP. 4: First-Line Treatment Options for Lower-Risk MDSJanuary 26th 2023
Thomas Cluzeau, MD, PhD provides an overview of first-line treatment options for symptomatic anemia in patients with lower-risk MDS, followed by a discussion of panelists’ treatment patterns and dosing strategies across the globe.
EP. 5: Second-Line Treatment Options for Lower-Risk MDSFebruary 2nd 2023
Dr Platzbecker outlines available second-line therapies for symptomatic anemia in patients with lower-risk MDS, highlighting differences in availability between the United States and Europe.
EP. 6: Case 1 Presentation: Lower-Risk MDS with Multiple Chromosomal AbnormalitiesFebruary 2nd 2023
Guillermo Garcia-Manero, MD presents a case of lower-risk MDS with chromosome 5q and 20q deletions and a p53 mutation, and discusses first- and second-line treatment selection.
EP. 7: Case 1: Expert Panelist CommentaryFebruary 9th 2023
Expert panelists reflect on the case presented by Dr Garcia-Manero and share their unique perspectives on how they might have approached treatment and followup for this patient in their own practice.
EP. 8: The Impact of p53 Mutations and 5q Deletions on Lower-Risk MDS Treatment ResponseFebruary 9th 2023
Dr Komrokji leads a discussion on emerging data on how p53 mutations and chromosome 5q deletions may affect prognosis, treatment response, and outcomes for patients with MDS.
EP. 9: Case 2 Presentation: Lower-Risk MDS-RS With an SF3B1 MutationFebruary 16th 2023
Dr Cluzeau introduces a second patient case of lower-risk MDS-RS with an SF3B1 mutation and symptomatic anemia, who received a first-line erythropoiesis-stimulating agent (ESA) and second-line luspatercept.
EP. 10: Case 2 Discussion and Considerations for Second-Line Treatment SelectionFebruary 16th 2023
The panelists discuss Dr Cluzeau’s presented case, emphasizing the importance of pathology reporting, and expand upon approaches to second-line treatment selection for patients with MDS-RS.
EP. 11: MEDALIST Trial Updates: ASH 2022 and EHA 2022February 23rd 2023
Dr Komrokji presents key data updates from the MEDALIST trial on luspatercept in patients with lower-risk MDS that were presented at the 2022 European Hematology Association (EHA) Congress and the 2022 ASH Annual Meeting.
EP. 13: Higher-Risk MDS: First- and Second-Line Therapies and Case 3 Presentation/DiscussionMarch 2nd 2023
The panel turns their focus to higher-risk MDS, starting with a discussion of first- and second-line treatment options, followed by a third and final case presentation and discussion led by Dr Platzbecker.